In an interview, David J. Benjamin, MD, explains the findings on gender makeup of NCCN guideline panels he presented at the 2026 ESMO Congress.
Commentary|Articles|November 2, 2026
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
Author(s)Lauren Banks, MD, PhD, Matt Flowers
Fact checked by: Sabrina Serani
Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.
Advertisement
Advertisement
Patients with advanced soft tissue sarcomas have limited treatment options after progression on first-line chemotherapy, and responses to immunotherapy have historically been less durable than those observed in some other malignancies. At the
Related to this article
ESMO 2026 Presidential Symposium III: ADC and immunotherapy highlights from the the ARTEMIS-011, TroFuse-005, KEYNOTE-C93, and MOIO trials.
Sara Lonardi, MD, discusses the final overall survival analysis of CheckMate-8HW from ESMO 2026 and its implications for first-line MSI-H/dMMR mCRC.
The first-in-class oral RIPTAC molecule JNJ-6143 reached a 75% overall response rate and significant declines in PSA in metastatic castration-resistant prostate cancer.
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Updated survival findings, perioperative treatment strategies, and circulating tumor DNA analyses highlight evolving approaches to genitourinary cancers.
Five ESMO 2026 abstracts report responses with 4 antibody-drug conjugates in ovarian cancer and a subcutaneous HER2-directed ADC plus PD-L1 inhibitor in cervical cancer.
Advertisement
Advertisement